Escherichia coli antibodies in alcoholic liver disease. Correlation to alcohol consumption, alcoholic hepatitis, and serum IgA. 1983

P Staun-Olsen, and M Bjørneboe, and H Prytz, and A C Thomsen, and F Orskov

In 41 patients with alcoholic liver disease, antibodies to 12 common Escherichia coli O antigens (expressed as number of O antibody reactions with an agglutination titre of greater than or equal to 40) and to immunoglobulins IgG, IgA, and IgM were studied for 8 weeks. In 18 patients (8 with cirrhosis, 10 with fatty liver) who continued drinking during this period no significant changes were found. In 23 patients (11 with cirrhosis, 12 with fatty liver) who stopped or reduced drinking, a significant decrease in the levels of E. coli O antibodies and IgA was found (p less than 0.05 and p less than 0.01, respectively). In these 41 patients and in an additional 43 patients with alcoholic liver disease the amount of E. coli O antibodies was compared with type of histological lesion. The levels of E. coli O antibodies were significantly higher in cirrhosis with alcoholic hepatitis (22 cases) than in cirrhosis without alcoholic hepatitis (17 cases) (p less than 0.05). In these 17 patients antibody levels were significantly higher than in 41 patients with fatty liver without alcoholic hepatitis (p less than 0.02). In all patients a significant correlation between the number of positive reactions to E. coli O antigens and serum IgA concentration was found (p less than 0.01). No microbes were cultured from the liver biopsies, and no E. coli O antigens were demonstrated in the liver tissue by immunohistochemistry. Our results support the hypothesis that the high levels of E. coli O antibodies in alcoholic liver diseases are due to failure of the liver to extract circulating antigens and gut-derived endotoxins.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008104 Liver Cirrhosis, Alcoholic FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING. Alcoholic Cirrhosis,Hepatic Cirrhosis, Alcoholic,Alcoholic Hepatic Cirrhosis,Alcoholic Liver Cirrhosis
D008108 Liver Diseases, Alcoholic Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS. Alcoholic Liver Diseases,Alcoholic Liver Disease,Liver Disease, Alcoholic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004927 Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI. E coli Infections,E. coli Infection,Infections, E coli,Infections, Escherichia coli,E coli Infection,E. coli Infections,Escherichia coli Infection,Infection, E coli,Infection, E. coli,Infection, Escherichia coli
D005235 Fatty Liver, Alcoholic Lipid infiltration of the hepatic parenchymal cells that is due to ALCOHOL ABUSE. The fatty changes in the alcoholic fatty liver may be reversible, depending on the amounts of TRIGLYCERIDES accumulated. Alcoholic Fatty Liver,Alcoholic Steatohepatitis
D005260 Female Females
D006519 Hepatitis, Alcoholic INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS. Alcoholic Hepatitis,Chronic Alcoholic Hepatitis,Hepatitis, Alcoholic, Chronic,Alcoholic Hepatitis, Chronic,Chronic Alcoholic Hepatitides

Related Publications

P Staun-Olsen, and M Bjørneboe, and H Prytz, and A C Thomsen, and F Orskov
January 1983, Journal of clinical pathology,
P Staun-Olsen, and M Bjørneboe, and H Prytz, and A C Thomsen, and F Orskov
October 1998, Alcoholism, clinical and experimental research,
P Staun-Olsen, and M Bjørneboe, and H Prytz, and A C Thomsen, and F Orskov
June 1997, Hepatology (Baltimore, Md.),
P Staun-Olsen, and M Bjørneboe, and H Prytz, and A C Thomsen, and F Orskov
June 2015, The Journal of the Association of Physicians of India,
P Staun-Olsen, and M Bjørneboe, and H Prytz, and A C Thomsen, and F Orskov
January 1987, Hepatology (Baltimore, Md.),
P Staun-Olsen, and M Bjørneboe, and H Prytz, and A C Thomsen, and F Orskov
April 2022, The Journal of the Association of Physicians of India,
P Staun-Olsen, and M Bjørneboe, and H Prytz, and A C Thomsen, and F Orskov
January 1973, Scandinavian journal of gastroenterology,
P Staun-Olsen, and M Bjørneboe, and H Prytz, and A C Thomsen, and F Orskov
September 1985, Clinical and experimental immunology,
P Staun-Olsen, and M Bjørneboe, and H Prytz, and A C Thomsen, and F Orskov
October 1981, Lancet (London, England),
P Staun-Olsen, and M Bjørneboe, and H Prytz, and A C Thomsen, and F Orskov
February 2011, Alimentary pharmacology & therapeutics,
Copied contents to your clipboard!